Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rex Fang & Innovation Equity Premium Income ETF vs Mesoblast Limited — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $43.47 (market cap $746.48M), while Mesoblast Limited trades at $13.8 (market cap $1.75B). The key difference: Mesoblast Limited is far larger — about 2.3× Rex Fang & Innovation Equity Premium Income ETF's market cap, and Rex Fang & Innovation Equity Premium Income ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rex Fang & Innovation Equity Premium Income ETF for 56 Days and Mesoblast Limited for 14 Days on average.
| FEPI | MESO | |
|---|---|---|
Market Cap | $746.48M | $1.75B |
Volume | 334,337 | 239,027 |
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $20.96 |
52-Week Low | $37.98 | $13.19 |
Typical Hold Time | 56 Days | 14 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FEPI (REX FANG & Innovation Equity Premium Income ETF) trades at $43.59, down 0.17% on the day, with a bullish technical signal supported by moving averages. The ETF employs a covered call strategy on AI and tech mega-caps, generating weekly dividends averaging $0.20-0.21 per share. Recent news highlights its high yield but notes underperformance versus peers in total return.
Outlook: High income potential via dividends but capped upside from call-writing. Risks include concentrated tech exposure, volatility sensitivity, and competitive pressure from alternative yield strategies. Neutral sentiment prevails amid yield appeal and growth constraints.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
